CA2532330A1 - Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation - Google Patents
Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation Download PDFInfo
- Publication number
- CA2532330A1 CA2532330A1 CA002532330A CA2532330A CA2532330A1 CA 2532330 A1 CA2532330 A1 CA 2532330A1 CA 002532330 A CA002532330 A CA 002532330A CA 2532330 A CA2532330 A CA 2532330A CA 2532330 A1 CA2532330 A1 CA 2532330A1
- Authority
- CA
- Canada
- Prior art keywords
- methods
- suffering
- human
- same
- highly selective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 208000020016 psychiatric disease Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 abstract 2
- 229960003770 reboxetine Drugs 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14196899P | 1999-07-01 | 1999-07-01 | |
| US60/141,968 | 1999-07-01 | ||
| US14413199P | 1999-07-16 | 1999-07-16 | |
| US60/144,131 | 1999-07-16 | ||
| US15825699P | 1999-10-06 | 1999-10-06 | |
| US60/158,256 | 1999-10-06 | ||
| US17038199P | 1999-12-13 | 1999-12-13 | |
| US60/170,381 | 1999-12-13 | ||
| CA002375908A CA2375908C (fr) | 1999-07-01 | 2000-06-22 | Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002375908A Division CA2375908C (fr) | 1999-07-01 | 2000-06-22 | Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2532330A1 true CA2532330A1 (fr) | 2001-01-11 |
| CA2532330C CA2532330C (fr) | 2009-04-21 |
Family
ID=36141768
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002532330A Expired - Fee Related CA2532330C (fr) | 1999-07-01 | 2000-06-22 | Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation |
| CA002543986A Expired - Fee Related CA2543986C (fr) | 1999-07-01 | 2000-06-22 | Inhibiteurs de recapture de la noradrenaline et methodes d'utilisation connexes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002543986A Expired - Fee Related CA2543986C (fr) | 1999-07-01 | 2000-06-22 | Inhibiteurs de recapture de la noradrenaline et methodes d'utilisation connexes |
Country Status (1)
| Country | Link |
|---|---|
| CA (2) | CA2532330C (fr) |
-
2000
- 2000-06-22 CA CA002532330A patent/CA2532330C/fr not_active Expired - Fee Related
- 2000-06-22 CA CA002543986A patent/CA2543986C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2543986A1 (fr) | 2001-01-11 |
| CA2532330C (fr) | 2009-04-21 |
| CA2543986C (fr) | 2009-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2375908A1 (fr) | Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation | |
| CA2427227A1 (fr) | Compose de lactam | |
| WO2002042462A3 (fr) | Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| AU2005202257C1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
| EA200000468A1 (ru) | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением | |
| WO2001009118A3 (fr) | Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire | |
| MY131810A (en) | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | |
| BR0214967A (pt) | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente | |
| WO2000064441A3 (fr) | Medicament | |
| CA2272584A1 (fr) | Nouveaux derives de pyrazole substitues pour le traitement de maladies cardio-vasculaires | |
| WO2003048164A3 (fr) | Antagonistes du recepteur a2a de l'adenosine | |
| CA2283255A1 (fr) | Utilisation d'enantiomeres r d'anti-inflammatoires non steroidiens pour la prevention de la maladie d'alzheimer | |
| WO1999045909A3 (fr) | Inhibition de l'angiogenese | |
| CA2340734A1 (fr) | Derive de pyridyl-4h-1,2,4-oxadiazine optiquement actif et son utilisation dans le traitement des maladies vasculaires | |
| WO2002005801A3 (fr) | Compositions pharmaceutiques et procedes d'utilisation de ces dernieres | |
| EP1632235A3 (fr) | utilisation d' inhibiteurs de recaptage de noradrenaline hautement selectifs pour traiter les maladies mentales | |
| WO2000076500A8 (fr) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| MX9805317A (es) | Agente para la profilaxis y el tratamiento de complicaciones diabeticas. | |
| WO2000004012A8 (fr) | COMPOSES SPECIFIQUES DU RECEPTEUR ADRENERGIQUE α1d HUMAIN ET SES UTILISATIONS | |
| CA2532330A1 (fr) | Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation | |
| AU6053496A (en) | The use of sertraline to treat post myocardial infarction patients | |
| IL164317A0 (en) | Statin therapy for enhancing cognitive maintenance | |
| MA26796A1 (fr) | Derive d'aminotetraline pour la therapie des maladies cardiovasculaires. | |
| GEP20043356B (en) | Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |